News Releases

Summary Toggle Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Lotion USP (Augmented), 0.05%

BUENA, N.J. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

February 14, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces the Appointment of Damian Finio as Chief Financial Officer

BUENA, N.J. , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced today that Damian Finio has been appointed Chief Financial Officer of Teligent, Inc. , effective February 5, 2018 . Mr.

January 26, 2018

PDF Version
Summary Toggle Teligent, Inc. to Present at the J.P. Morgan 36th Annual Healthcare Conference January 10th

BUENA, N.J. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the J.P. Morgan 36 th Annual Healthcare Conference. The Conference is taking place January 8-11, 2018 at the Westin St.

January 3, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces First FDA Generic Approval of Hydrocortisone Butyrate Lotion 0.1%

BUENA, N.J. , Nov. 22, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

November 22, 2017

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Erythromycin Topical Solution USP, 2%

BUENA, N.J. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

November 21, 2017

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%

BUENA, N.J. , Nov. 10, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

November 10, 2017

PDF Version
Summary Toggle Teligent, Inc. Announces Third Quarter 2017 Results

BUENA, N.J. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2017 . Third Quarter 2017 Highlights Total revenues of $13.7 million in the

November 6, 2017

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Third Quarter 2017 Results

BUENA, N.J. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Monday November 6, 2017 to discuss the 3rd quarter 2017 financial results and business

October 26, 2017

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Partnered ANDA for Desonide Lotion, 0.05%

BUENA, N.J. , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s partnered abbreviated new drug application (ANDA) from the U.S.

October 2, 2017

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Triamcinolone Acetonide Cream USP, 0.1%

BUENA, N.J. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

September 19, 2017

PDF Version